The Potential of Wharton’s Jelly Derived Mesenchymal Stem Cells in Treating Patients with Cystic Fibrosis
Cystic fibrosis (CF) is a life-threatening autosomal recessive multi-organ disorder with the mean incidence of 0.737 per 10,000 people worldwide. Despite many advances in therapy, patients fail to have a satisfactory quality of life. The end-stage lung disease still accounts for significant mortality and puts patients in the need of lung transplantation. Even though the disease is monogenic, the trials of topical gene transfer into airway epithelial cells have so far been disappointing. It is proven that stem cells can be differentiated into type II alveolar epithelial cells. Wharton’s jelly-derived mesenchymal stem cells (MSC) from non-CF carrier third-party donors could be an effective alternative to bone marrow or embryonic stem cells. The harvesting process is an easy and ethically uncontroversial procedure. The MSC cell should be applied through repetitive infusions due to rapid lung epithelial cell turnover. However, the low stem cell incorporation remains a problem. Pre-clinical studies imply that even 6–10 % of the wild-type cystic fibrosis transmembrane conductance regulator (CFTR) expression could be enough to restore chloride secretion. The route of administration, the optimal dose, as well as the intervals between infusions have yet to be determined. This review discusses the clinical potential of mesenchymal stem cell in CF patients.
KeywordsCystic fibrosis Lung diseases Stem cell therapy Umbilical cord
DB and DG contributed equally to this work.
Conflicts of Interest
The authors declare no conflicts of interest in relation to this article.
- Boruczkowski D, Ołdak T, Czaplicka I, Murzyn I, Olkowicz A, Pawelec K, Balogh I, Géza V, Pirciog D, Stefan R, Soguero C, Kalwak K, Ussowicz M, Mielcarek M, Chybicka A, Drabko K, Kowalczyk J, Michalski P (2012) The collection and cultivation of umbilical cord derived cells for potential clinical use. Bone Marrow Transplant 47(Suppl 1):280–281Google Scholar
- Bruscia EM, Price JE, Cheng EC, Weiner S, Caputo C, Ferreira EC, Egan ME, Krause DS (2006) Assessment of cystic fibrosis transmembrane conductance regulator (CFTR) activity in CFTR-null mice after bone marrow transplantation. Proc Natl Acad Sci U S A 103:2965–2970PubMedCentralPubMedCrossRefGoogle Scholar
- Leblond AL, Naud P, Forest V, Gourden C, Sagan C, Romefort B, Mathieu E, Delorme B, Collin C, Pagès JC, Sensebé L, Pitard B, Lemarchand P (2009) Developing cell therapy techniques for respiratory disease: intratracheal delivery of genetically engineered stem cells in a murine model of airway injury. Hum Gene Ther 20(11):1329–1343PubMedCentralPubMedCrossRefGoogle Scholar
- Painter RG, Valentine VG, Lanson NA, Leidal K, Zhang Q, Lombard G, Thompson C, Viswanathan A, Nauseef WM, Wang G, Wang G (2006) CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry 45(34):10260–10269PubMedCentralPubMedCrossRefGoogle Scholar
- Paracchini V, Carbone A, Colombo F, Castellani S, Mazzucchelli S, Gioia SD, Degiorgio D, Seia M, Porretti L, Colombo C, Conese M (2012) Amniotic mesenchymal stem cells: a new source for hepatocyte-like cells and induction of CFTR expression by coculture with cystic fibrosis airway epithelial cells. J Biomed Biotechnol 2012:575471PubMedCentralPubMedCrossRefGoogle Scholar
- Wang G, Bunnell BA, Painter RG, Quiniones BC, Tom S, Lanson NA Jr, Spees JL, Bertucci D, Peister A, Weiss DJ, Valentine VG, Prockop DJ, Kolls JK (2005) Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis. Proc Natl Acad Sci U S A 102(1):186–191PubMedCentralPubMedCrossRefGoogle Scholar